What are Proteasome Inhibitor drugs?

Proteasome Inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting Proteasome subunit beta type-5). 3 are currently marketed, with 8 more in clinical development.

What are the marketed Proteasome Inhibitor drugs?

Marketed Proteasome Inhibitor drugs include Ninlaro, Bortezomib (B), Velcade.

Proteasome Inhibitor

3 marketed 5 in Phase 3 3 in Phase 2

This page covers all Proteasome Inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Proteasome subunit beta type-5, 26S proteasome, 26S proteasome chymotrypsin-like activity.

Targets

Proteasome subunit beta type-5 · 26S proteasome · 26S proteasome chymotrypsin-like activity · Proteasome · 20S proteasome

Marketed (3)

Ninlaro · Takeda · Oncology · 600
Ninlaro blocks the action of proteasomes, which are cellular complexes that break down and recycle proteins.
Bortezomib (B) · National Cancer Institute (NCI) · Oncology
Bortezomib inhibits the 26S proteasome, preventing the degradation of proteins that regulate cell cycle and apoptosis, leading to cancer cell death.
Velcade · Shilpa · Oncology
Reversible inhibitor of 26S proteasome chymotrypsin-like activity preventing ubiquitinated protein degradation.

Phase 3 pipeline (5)

VELCADE Administered by intravenous infusion · Millennium Pharmaceuticals, Inc. · Oncology
VELCADE (bortezomib) is a proteasome inhibitor that blocks the degradation of proteins, causing cancer cells to accumulate toxic protein levels and undergo apoptosis.
Velcade, Thalidomide, Dexamethasone · University of Arkansas · Oncology
Velcade (bortezomib) is a proteasome inhibitor that blocks the action of proteasomes, which are complexes that break down proteins in cells.
VELCADE Administered by subcutaneous injection · Millennium Pharmaceuticals, Inc. · Oncology
VELCADE is a proteasome inhibitor that blocks the action of proteasomes in cells, leading to cell death.
TLK286 HCl for injection · Telik · Oncology
TLK286 HCl for injection is a proteasome inhibitor.
VBMCP/VBAD/Velcade · PETHEMA Foundation · Oncology
Velcade works by inhibiting the proteasome, a complex within cells that breaks down proteins.

Phase 2 pipeline (3)

Carfilzomib, proteasome inhibitor; intravenous · Pfizer · Oncology
Proteasome inhibitor
Bortezomib, Rituximab, Dexamethasone · Meletios A. Dimopoulos · Oncology
Proteasome inhibitor
Bortezomib, Dexamethasone, Rituximab · European Myeloma Network B.V. · Oncology
Bortezomib inhibits the 26S proteasome, disrupting protein degradation and inducing apoptosis in cancer cells.